ATNX
| Market cap | $69.11M |
|---|---|
| Enterprise value | N/A |
| Revenue | $102.821M |
|---|---|
| EBITDA | -$67.61 |
| Income | -$103.43 |
| Revenue Q/Q | -65.38% |
| Revenue Y/Y | -13.96% |
| P/E | 0.00 |
|---|---|
| Forward P/E | N/A |
| EV/Sales | 0.08 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | 0.19 |
| Price/Sales | 0.67 |
| P/FCF | N/A |
| Price/Book | -10.62 |
| Book/Share | 0.00 |
| Cash/Share | 3.64 |
| FCF yield | -109.14% |
| Volume | 1.755M / 12.583k |
|---|---|
| Relative vol. | 139.47 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | -15.15% |
| Est. EPS Q/Q | -54.55% |
| Profit margin | -100.59% |
|---|---|
| Oper. margin | -68.60% |
| Gross margin | 25.97% |
| EBIT margin | -74.69% |
| EBITDA margin | -65.76% |
| Ret. on assets | -46.42% |
|---|---|
| Ret. on equity | -606.04% |
| ROIC | -30.54% |
| ROCE | -86.60% |
| Debt/Equity | -31.36 |
|---|---|
| Net debt/EBITDA | -5.12 |
| Current ratio | 1.09 |
| Quick ratio | 0.72 |
| Volatility | 532.91% |
|---|---|
| Beta | 0.00 |
| RSI | 31.69 |
|---|
| Insider ownership | 9.87% |
|---|---|
| Inst. ownership | 29.42% |
| Shares outst. | 8.663M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 3.15% |
| Short ratio | 3.79 |
| Dividend | N/A |
|---|---|
| Dividend yield | N/A |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | N/A |
Monday, 2 May 2022
|
|
| Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma a - Yahoo Finance | |
Thursday, 13 January 2022
|
|
| Inside the Athenex-ImmunityBio deal — and the California company's employment plans | |
Tuesday, 30 November 2021
|
|
| Athenex to Host Key Opinion Leader Webinar on CAR-NKT Approach to Cancer - Yahoo Finance | |
Sunday, 7 November 2021
|
|
| Athenex, inc Q3 2021 Earnings Call Transcript | |
Friday, 7 May 2021
|
|
| Athenex, Inc. Q1 2021 Earnings Call Transcript | |
Wednesday, 5 May 2021
|
|
| Athenex Snaps Up Kuur Therapeutics For $185M; Street Sees 133.7% Upside | |
Monday, 3 May 2021
|
|
| MAY 3, 2021 ATNX INVESTOR DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc. | |
Sunday, 2 May 2021
|
|
| ATNX DEADLINE ALERT: HAGENS BERMAN, National Trial Attorneys, Alerts Athenex Investors to Monday May 3rd Application Deadline in Securities Class Action, Advises Investors with Losses to Contact the Firm Immediately | |
Friday, 30 April 2021
|
|
| SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Athenex, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2021 - ATNX | |
| ATNX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Athenex, Inc. | |
| ATNX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 3, 2021 in the Class Action Filed on Behalf of Athenex, Inc. Limited Shareholders | |
| ATNX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Athenex, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: May 3, 2021 | |
Thursday, 29 April 2021
|
|
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Athenex, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2021 - ATNX | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Athenex Investors to May 3rd Securities Class Action Deadline, Encourages Investors with Losses to Contact the Firm Immediately | |
| ATNX FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Athenex, Inc. Investors With Losses to Secure Counsel Before Important Monday Deadline in Securities Class Action - ATNX | |
Wednesday, 28 April 2021
|
|
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Athenex, Inc., of Class Action Lawsuit and Upcoming Deadline - ATNX | |
| DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Athenex, Inc. and Encourages Investors to Contact the Firm | |
| ATHENEX INVESTOR ALERT: Shareholder Lawsuit Filed | |
| Bronstein, Gewirtz & Grossman, LLC Reminds Athenex, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: May 3, 2021 | |
| MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | |
Tuesday, 27 April 2021
|
|
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Athenex Investors of May 3rd Application Deadline in Securities Class Action, Investors with Losses Should Contact the Firm Before Deadline | |
Monday, 26 April 2021
|
|
| Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Athenex, Inc. and May 3 Deadline | |
| 7-DAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | |
Saturday, 24 April 2021
|
|
| Rosen, A Leading Law Firm, Encourages Athenex, Inc. Investors with Losses Over $100K to Secure Counsel Before Important May 3 Deadline in Securities Class Action - ATNX | |
Friday, 23 April 2021
|
|
| ROSEN, SKILLED INVESTOR COUNSEL, Encourages Athenex, Inc. Investors With Losses Over $100K to Secure Counsel Before Important May 3 Deadline in Securities Class Action - ATNX | |
| ATNX 10-DAY DEADLINE ALERT: HAGENS BERMAN Notifies Athenex Investors of May 3rd Application Deadline in Securities Class Action, Encourages Investors with Losses to Contact Its Attorneys | |
| MAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | |
Thursday, 22 April 2021
|
|
| ATHENEX INVESTOR ALERT: Class Action Lawsuit Filed | |
Wednesday, 21 April 2021
|
|
| ATNX 12-DAY DEADLINE ALERT: HAGENS BERMAN Reminds Athenex Investors of May 3rd Application Deadline in Securities Class Action, Encourages Investors with Losses to Contact Its Attorneys | |
| Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Velodyne Lidar, Renewable Energy Group, Athenex, and Ontrak and Encourages Investors to Contact the Firm - Yahoo Finance | |
Tuesday, 20 April 2021
|
|
| LAWSUIT FILED: Block & Leviton LLP Has Filed a Lawsuit Against Athenex, Inc. for Securities Fraud; Investors Who Lost Money Should Contact the Firm | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Athenex Investors to May 3rd Deadline in Securities Class Action, Encourages Investors with Losses to Contact Its Attorneys | |
Monday, 19 April 2021
|
|
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Athenex, Inc., of Class Action Lawsuit and Upcoming Deadline - ATNX | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Joe Annoni Chief Financial Officer | Option 22 Feb 2023 | $1,663 |
| Timothy De Vere Cook See Remarks | Option 16 Sep 2022 | $919 |
| Daniel Lang Pres Cell Therapy and VP Corp Dev | Option 16 Sep 2022 | $5,108 |
| Johnson Yiu Nam Lau CEO and Chairman of the Board | Buy 19 Aug 2022 | $9,000 |
| John Vierling Director | Option 3 Aug 2022 | $4,355 |
| Benson Kwan Hung Tsang Director | Option 3 Aug 2022 | $5,806 |
| Robert J. Spiegel Director | Option 3 Aug 2022 | $5,080 |
| Jordan Kanfer Director | Option 3 Aug 2022 | $4,355 |
| Manson Fok Director | Option 3 Aug 2022 | $3,629 |
| Stephanie A Davis Director | Option 3 Aug 2022 | $5,080 |
| Jinn Wu Director | Buy 3 Aug 2022 | $4,200 |
Powered by
Robintrack.
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Johnson Lau (59) Chief Executive Officer and Chairman of the Board since 2011 | 59 | 2011 | $4,483,840 |
| Rudolf Kwan (67) Chief Medical Officer since 2014 | 67 | 2014 | $1,473,850 |
| Jeffrey Yordon (71) Chief Operating Officer, President, and Athenex Pharmaceutical Division since 2017 | 71 | 2017 | $1,387,830 |
| Randoll Sze (39) Chief Financial Officer since 2018 | 39 | 2018 | $942,989 |
| Simon Pedder (59) Chief Business and Strategy Officer - Proprietary Products since 2019 | 59 | 2019 | $860,546 |
| Jeffrey M. Yordon (72) COO and Pres of Athenex Pharmaceutical Division | 72 | $693,454 | |
| Dr. Rudolf Kwan M.D., M.B., B.S. (68) Chief Medical Officer | 68 | $483,205 | |
| Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D. (61) Chairman and CEO | 61 | $480,747 | |
| Benson Tsang (55) Independent Director since 2018 | 55 | 2018 | $184,036 |
| Stephanie Davis (56) Independent Director since 2019 | 56 | 2019 | $156,239 |
| Kim Campbell (73) Lead Independent Director since 2015 | 73 | 2015 | $151,960 |
| Jinn Wu (71) Independent Director since 2007 | 71 | 2007 | $149,960 |
| Jordan Kanfer (50) Independent Director since 2019 | 50 | 2019 | $117,740 |
| John Vierling (74) Independent Director since 2019 | 74 | 2019 | $114,740 |
| Manson Fok (63) Director since 2015 | 63 | 2015 | $105,807 |
| Robert Spiegel (70) Director since 2020 | 70 | 2020 | |
| Daniel Lang | 2019 | ||
| Tim McCarthy | 2017 | ||
| William Zuo (58) President and China Division since 2015 | 58 | 2015 | |
| Dr. Wing-Kai Chan | |||
| John W. Matthei | |||
| Caileigh Dougherty | |||
| Michael Smolinski Ph.D. | |||
| Steven J. Adams (53) Interim Chief Accounting Officer | 53 | ||
| Daniel Lang M.D. | |||
| Jacqueline Li | |||
| Steven Rubis | |||
| Teresa Brophy Bair | |||
| Dr. Allen Barnett |
athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
- Health Care > Biotechnology
- Athenex Inc, Conventus Building, Buffalo 14203, United States
- 716 427 2950
- Investor relations
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Dec 2022 | 30 Sep 2022 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $35.62 | $40.412 | |||
| Short term investments | $1.071 | $1.034 | |||
| Net receivables | $27.865 | $32.912 | |||
| Inventory | $42.654 | $42.039 | |||
| Total current assets | $124.929 | $126.706 | |||
| Long term investments | |||||
| Property, plant & equipment | $6.043 | $8.351 | |||
| Goodwill & intangible assets | $72.112 | $72.168 | |||
| Total noncurrent assets | $79.126 | $101.644 | |||
| Total investments | $1.071 | $1.034 | |||
| Total assets | $204.055 | $228.35 | |||
| Current liabilities | |||||
| Accounts payable | $33.682 | $25.071 | |||
| Deferred revenue | |||||
| Short long term debt | $39.214 | $16.953 | |||
| Total current liabilities | $114.879 | $84.903 | |||
| Long term debt | $89.889 | $105.781 | |||
| Total noncurrent liabilities | $113.357 | $136.211 | |||
| Total debt | $129.103 | $122.734 | |||
| Total liabilities | $228.236 | $221.114 | |||
| Stockholders' equity | |||||
| Retained earnings | -$1,016.839 | -$982.658 | |||
| Other stockholder equity | $0.887 | $2.987 | |||
| Total stockholder equity | -$6.506 | $24.845 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $35.62 | $51.702 | ||
| Short term investments | $1.071 | $10.207 | ||
| Net receivables | $27.865 | $26.637 | ||
| Inventory | $42.654 | $34.685 | ||
| Total current assets | $124.929 | $133.396 | ||
| Long term investments | ||||
| Property, plant & equipment | $6.043 | $34.221 | ||
| Goodwill & intangible assets | $72.112 | $71.896 | ||
| Total noncurrent assets | $79.126 | $134.052 | ||
| Total investments | $1.071 | $10.207 | ||
| Total assets | $204.055 | $267.448 | ||
| Current liabilities | ||||
| Accounts payable | $33.682 | $16.742 | ||
| Deferred revenue | ||||
| Short long term debt | $39.214 | $49.79 | ||
| Total current liabilities | $114.879 | $96.047 | ||
| Long term debt | $89.889 | $107.95 | ||
| Total noncurrent liabilities | $113.357 | $136.949 | ||
| Total debt | $129.103 | $157.74 | ||
| Total liabilities | $228.236 | $232.996 | ||
| Stockholders' equity | ||||
| Retained earnings | -$1,016.839 | -$913.412 | ||
| Other stockholder equity | $0.887 | -$0.487 | ||
| Total stockholder equity | -$6.506 | $51.131 | ||
Income statement
| (in millions USD) | 31 Dec 2022 | 30 Sep 2022 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $8.633 | $33.53 | |||
| Cost of revenue | $2.461 | $27.736 | |||
| Gross profit | $6.172 | $5.794 | |||
| Operating activities | |||||
| Research & development | $15.365 | $9.214 | |||
| Selling, general & administrative | $4.463 | $9.438 | |||
| Total operating expenses | $19.907 | $18.652 | |||
| Operating income | -$13.735 | -$12.858 | |||
| Income from continuing operations | |||||
| EBIT | -$23.686 | -$12.802 | |||
| Income tax expense | -$0.259 | $0.596 | |||
| Interest expense | $10.754 | $6.271 | |||
| Net income | |||||
| Net income | -$34.181 | -$19.669 | |||
| Income (for common shares) | -$34.181 | -$19.669 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $102.821 | $120.181 | ||
| Cost of revenue | $76.118 | $82.406 | ||
| Gross profit | $26.703 | $37.775 | ||
| Operating activities | ||||
| Research & development | $51.758 | $80.197 | ||
| Selling, general & administrative | $44.88 | $72.553 | ||
| Total operating expenses | $96.717 | $222.169 | ||
| Operating income | -$70.014 | -$184.394 | ||
| Income from continuing operations | ||||
| EBIT | -$77.237 | -$189.63 | ||
| Income tax expense | $0.347 | -$10.604 | ||
| Interest expense | $25.843 | $20.742 | ||
| Net income | ||||
| Net income | -$103.427 | -$199.768 | ||
| Income (for common shares) | -$103.427 | -$199.768 | ||
Cash flows
| (in millions USD) | 31 Dec 2022 | 30 Sep 2022 | |||
|---|---|---|---|---|---|
| Net income | -$34.181 | -$19.669 | |||
| Operating activities | |||||
| Depreciation | $0.106 | $0.746 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $1.44 | $1.409 | |||
| Total cash flows from operations | -$14.394 | -$16.274 | |||
| Investing activities | |||||
| Capital expenditures | $0.056 | -$0.113 | |||
| Investments | $0.05 | $0.058 | |||
| Total cash flows from investing | $12.505 | -$0.81 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $3.595 | $20.647 | |||
| Net borrowings | -$3.372 | -$8.873 | |||
| Total cash flows from financing | $0.103 | $20.781 | |||
| Effect of exchange rate | -$3.006 | $0.751 | |||
| Change in cash and equivalents | -$1.786 | $3.697 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Net income | -$103.427 | -$199.768 | ||
| Operating activities | ||||
| Depreciation | $2.322 | $4.682 | ||
| Business acquisitions & disposals | $1.526 | |||
| Stock-based compensation | $6.326 | $9.207 | ||
| Total cash flows from operations | -$75.014 | -$142.379 | ||
| Investing activities | ||||
| Capital expenditures | -$0.417 | -$8.398 | ||
| Investments | $9.596 | $128.936 | ||
| Total cash flows from investing | $57.902 | $104.984 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $28.905 | $2.843 | ||
| Net borrowings | -$35.436 | -$0.203 | ||
| Total cash flows from financing | $1.564 | $2.462 | ||
| Effect of exchange rate | -$0.534 | $0.548 | ||
| Change in cash and equivalents | -$15.548 | -$34.933 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2023 Q2 | Acadian Asset Management |
Sold out
|
48,556 | $6 |
| 2023 Q2 | B. Riley Wealth Advisors |
Sold out
|
22,497 | $2,925 |
| 2023 Q1 | National Bank Of Canada fi/ |
Sold out
|
175 | $228 |
| 2022 Q4 | Renaissance Technologies |
Sold out
|
1,205,528 | $178 |
| 2022 Q3 | Citadel Advisors |
-86.81%
|
77,162 | $20 |
| 2022 Q3 | Millennium Management |
-8.92%
|
4,169,818 | $1,123 |
| 2022 Q2 | Occudo Quantitative Strategies L.P. |
Sold out
|
151,987 | $62 |
| 2022 Q2 | Aqr Capital Management |
Sold out
|
109,447 | $45 |
| 2022 Q2 | D. E. Shaw & Co |
Sold out
|
29,409 | $12 |
| 2022 Q2 | Brinker Capital Investments |
Sold out
|
27,688 | $11 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Millennium Management | 48.13% | 4,169,818 | |
| Alyeska Investment L.P. | 23.09% | 2,000,000 | |
| Renaissance Technologies | 13.92% | 1,205,528 | |
| Greenwoods Asset Management Ltd | 5.75% | 498,510 | |
| Occudo Quantitative Strategies L.P. | 1.75% | 151,987 | |
| Tiaa Cref Investment Management | 1.51% | 130,387 | |
| Aqr Capital Management | 1.26% | 109,447 | |
| Parametric Portfolio Associates | 1.21% | 104,740 | |
| Spearhead Capital Advisors | 1.12% | 97,169 | |
| Citadel Advisors | 0.89% | 77,162 |
Sign up